Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Syndax Pharmaceuticals Inc
SNDX | US
21.00
USD-1.08
-4.89%
SNDX | US
About Syndax Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
23/04/2026
Close
21.00
Open
22.15
High
22.50
Low
20.96
Syndax Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613 which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab a monoclonal antibody that blocks the colony stimulating factor 1 or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing development and commercialization of Entinostat. Syndax Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Waltham Massachusetts.
View LessSNDX | US
Risk
45.6
Sharpe
0.90
Luna's Score
49/100
Recommendation
Hold
Luna says (SNDX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
35.4%1 month
45.6%3 months
44.3%6 months
54.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.90
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-105.26
Ent. to rev.
360.41
PEG
-
Other Fundamentals
EBITDA
-287.98M
MarketCap
1.79B
MarketCap(USD)
1.79B
Div. yield
-
Op. margin
-2.12K
Erngs. growth
-
Rev. growth
33.30K
Ret. on equity
-63.30
Short ratio
8.43
Short perc.
11.95
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
4.25
Range1M
4.63
Range3M
6.38
Volumes: Market Activity
Rel. volume
1.73
Price X volume
52.25M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -105.26 | - | Cheaper |
| Ent. to Revenue | 360.41 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.90 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 44.29 | - | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 1.79B | - | Emerging |
